33.02USD-0.18%Mkt Cap: 6.79B USDP/E: —Last update: 2026-06-01
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.79B USD
Enterprise Value5.93B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-505.61M USD
Revenue/Share—
Last Price33.02 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees315
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.67
PEG—
EV/EBITDA-11.14
EV/Revenue—
P/S—
P/B6.87
EPS (TTM)-2.77
EPS (Forward)-2.44
52W Range
14.2985% of range36.28
52W High36.28 USD
52W Low14.29 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.30%
ROA-52.83%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-407.31M USD
CapEx (TTM)8.00K USD
FCF Margin—
FCF Yield-3.45%
Net Debt-902.04M USD
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.00
Current Ratio9.09
Quick Ratio8.68
Book Value/Sh4.850 USD
Cash/Share4.394 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)44.71 USD
Target Range24.00 USD – 66.00 USD
# Analysts17
Ownership
Shares Out.205.31M
Float78.82M
Insiders56.76%
Institutions54.74%
Short Interest
Short Ratio13.3d
Short % Float22.44%
Short % Out.9.92%
Shares Short20.37M
Short (prev mo.)19.50M
Technical
SMA 5027.45 (+20.3%)
SMA 20023.41 (+41.0%)
Beta0.70
S&P 52W Chg27.94%
Avg Vol (30d)2.07M
Avg Vol (10d)3.67M
Technical Indicators
RSI (14)61.6
MACD1.7297
MACD Signal1.3425
MACD Hist.+0.3872
BB Upper36.23 USD
BB Middle30.09 USD
BB Lower23.95 USD
BB Width40.82%
ATR (14)1.870 USD
Vol Ratio (20d)0.31x